Large-Scale Production and Structural and Biophysical Characterizations of the Human Hepatitis B Virus Polymerase
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Hepatitis B virus (HBV) is a major human pathogen that causes serious liver disease and 600,000 deaths annually. Approved therapies for treating chronic HBV infections usually target the multifunctional viral polymerase (hPOL). Unfortunately, these therapies—broad-spectrum antivirals—are not general cures, have side effects, and cause viral resistance. While hPOL remains an attractive therapeutic target, it is notoriously difficult to express and purify in a soluble form at yields appropriate for structural studies. Thus, no empirical structural data exist for hPOL, and this impedes medicinal chemistry and rational lead discovery efforts targeting HBV. Here, we present an efficient strategy to overexpress recombinant hPOL domains in Escherichia coli , purifying them at high yield and solving their known aggregation tendencies. This allowed us to perform the first structural and biophysical characterizations of hPOL domains. Apo-hPOL domains adopt mainly α-helical structures with small amounts of β-sheet structures. Our recombinant material exhibited metal-dependent, reverse transcriptase activity in vitro , with metal binding modulating the hPOL structure. Calcomine orange 2RS, a small molecule that inhibits duck HBV POL activity, also inhibited the in vitro priming activity of recombinant hPOL. Our work paves the way for structural and biophysical characterizations of hPOL and should facilitate high-throughput lead discovery for HBV. IMPORTANCE The viral polymerase from human hepatitis B virus (hPOL) is a well-validated therapeutic target. However, recombinant hPOL has a well-deserved reputation for being extremely difficult to express in a soluble, active form in yields appropriate to the structural studies that usually play an important role in drug discovery programs. This has hindered the development of much-needed new antivirals for HBV. However, we have solved this problem and report here procedures for expressing recombinant hPOL domains in Escherichia coli and also methods for purifying them in soluble forms that have activity in vitro . We also present the first structural and biophysical characterizations of hPOL. Our work paves the way for new insights into hPOL structure and function, which should assist the discovery of novel antivirals for HBV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When combined with ion mobility, a gas phase–based separation, native MS becomes a valuable technique for structural virologists to determine the size and shape of intermediate and mature capsid structures (Figure 2) (25–27).”
From The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology (2014) · cites this paper as [26]
Citations
Cites
Sreerama, N., & Woody, R. W. (2000) · Analytical Biochemistry · doi:10.1006/abio.2000.4880 · Cited by 2,992 · cited 1×
“Deconvolution of the far-UV CD spectrum suggested apo-TP1–192 contained 31% -helix and 16% -sheet, values that agreed well with the sequence-based structural predictions (32% -helix and 10% -sheet, respectively) (Table 1) (57, 66).”
BackgroundHsp70 chaperones: Cellular functions and molecular mechanism
Mayer, M. P., & Bukau, B. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4464-6 · Cited by 2,865
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Ott, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.116 · Cited by 1,843 · cited 1×
“and causes 600,000 deaths annually (1).”
NPS@: Network Protein Sequence Analysis
Combet, C., Blanchet, C., Geourjon, C., & Deléage, G. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01540-6 · Cited by 1,757 · cited 9×
“tools and hydrophobic cluster analysis (HCA) (57, 58) to help”
BackgroundMethodInfluentialOrigin and evolution of retroelements based upon their reverse transcriptase sequences
Xiong, Y., & Eickbush, T. H. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07536.x · Cited by 1,374
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Molecular Interaction Studies Using Microscale Thermophoresis
Jerabek-Willemsen, M., Wienken, C. J., Braun, D., Baaske, P., & Duhr, S. (2011) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2011.0380 · Cited by 812 · cited 2×
“The differences in normalized fluorescence intensities in the selected data range (gray bars) were used to determine the binding curve shown in panel B (76).”
BackgroundMethodIsothermal Titration Calorimetry of Protein–Protein Interactions
Pierce, M. M., Raman, C. S., & Nall, B. T. (1999) · Methods · doi:10.1006/meth.1999.0852 · Cited by 576
Research works printed but not linked: 2
- TheisenA. 2000. Refractive increment data book for polymer and biomolecular scientists. Nottingham University Press, Nottingham, United Kingdom.
- 10.01089/adt.2011.0380 · doi:10.01089/adt.2011.0380
Cited by
Zeisel, M. B., Lucifora, J., Mason, W. S., Sureau, C., Beck, J., Levrero, M., Kann, M., Knolle, P. A., Benkirane, M., Durantel, D., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308943 · Cited by 256
Königer, C., Wingert, I., Marsmann, M., Rösler, C., Beck, J., & Nassal, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409986111 · Cited by 239
“bond was sterically shielded; the notorious problems in keeping recombinant P protein soluble (9, 51) support this view.”
BackgroundMenéndez-Arias, L., Álvarez, M., & Pacheco, B. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.04.005 · Cited by 163
Menéndez-Arias, L., Sebastián-Martín, A., & Álvarez, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.12.019 · Cited by 123
The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology
Greco, T. M., Diner, B. A., & Cristea, I. M. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085527 · Cited by 67
Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus
Tramontano, E., Corona, A., & Menéndez-Arias, L. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104613 · Cited by 53
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities
Bouclé, S., Bassit, L., Ehteshami, M., & Schinazi, R. F. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.07.001 · Cited by 27
Mapping of Functional Subdomains in the Terminal Protein Domain of Hepatitis B Virus Polymerase
Clark, D. N., Flanagan, J. M., & Hu, J. (2016) · Journal of Virology · doi:10.1128/jvi.01785-16 · Cited by 25
“It was notable that the predicted helix 6 spans the traditional boundary between the TP and spacer domains, which means that a more realistic boundary may be after this helix, with the TP domain ending at position 192, as has also been suggested recently (36).”
BackgroundYasutake, Y., Hattori, S.-I., Tamura, N., Matsuda, K., Kohgo, S., Maeda, K., & Mitsuya, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-59775-w · Cited by 25
Yasutake, Y., Hattori, S.-I., Hayashi, H., Matsuda, K., Tamura, N., Kohgo, S., Maeda, K., & Mitsuya, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-19602-9 · Cited by 18
Buhlig, T. S., Bowersox, A. F., Braun, D. L., Owsley, D. N., James, K. D., Aranda, A. J., Kendrick, C. D., Skalka, N. A., & Clark, D. N. (2020) · Viruses · doi:10.3390/v12050570 · Cited by 16
“Representative amino acid sequences for several HBV species were used to predict secondary structures using SABLE [76], matching previously published secondary structure predictions [39,42].”
MethodNakajima, S., Watashi, K., Fukano, K., Tsukuda, S., Wakae, K., Aizaki, H., Muramatsu, M., Wakita, T., & Toyoda, T. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01643-0 · Cited by 15
Nakamura, A., Tamura, N., & Yasutake, Y. (2015) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x15017896 · Cited by 13
“Although largescale purification of recombinant HBV Pol by refolding has recently been reported (Voros et al., 2014), it is still a challenging process to obtain active and stable HBV Pol in vitro for X-ray structural analyses and high-throughput drug screening.”
MethodRuiz, F. X., Hoang, A., Dilmore, C. R., DeStefano, J. J., & Arnold, E. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.016 · Cited by 11
Yasutake, Y., Hattori, S.-I., Tamura, N., Matsuda, K., Kohgo, S., Maeda, K., & Mitsuya, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.026 · Cited by 8
Glebe, D., & Geipel, A. (2014) · Intervirology · doi:10.1159/000360950 · Cited by 8
Cytoplasm Hydrogelation-Mediated Cardiomyocyte Sponge Alleviated Coxsackievirus B3 Infection
Wang, J., Liu, T., Gu, S., Yang, H.-H., Xie, W., Cheng, G., & Gu, D. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01983 · Cited by 9
Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
Zhang, B., Chai, D.-P., Wu, Y.-H., Qiu, L., Zhang, Y.-Y., Ye, Z., & Yu, X. (2019) · Current Drug Targets · doi:10.2174/1389450120666190729115646 · Cited by 7
Ohsaki, E., & Ueda, K. (2020) · Viruses · doi:10.3390/v12080840 · Cited by 6
“Protein purification was performed according to methods used in a previous study [8].”
MethodDörnbrack, K., Beck, J., & Nassal, M. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010362 · Cited by 6
“HBV P protein, however, has never shown strictly ε -dependent priming activity in any such system, and neither when recombinantly expressed in insect cells [35] or multi-step purified from E . coli [36].”
Yasutake, Y., Hattori, S.-I., Kumamoto, H., Tamura, N., Maeda, K., & Mitsuya, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-66505-z · Cited by 3
Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity
Toyoda, T., Wang, Y., Wen, Y., & Tanaka, Y. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.113642 · Cited by 3
Hu, S., Xiong, H., Kang, X.-Z., Wang, S., Zhang, T., Yuan, Q., & Tian, D. (2020) · Virulence · doi:10.1080/21505594.2020.1869391 · Cited by 3
“HBV pol is a viral nuclear protein that is difficult to detect [18,19].”
Backgroundde Castro, S., Fernández‐Cureses, G., Andreï, G., Snoeck, R., Sánchez‐Murcia, P. A., Korba, B. A., Gago, F., Balzarini, J. M., & Camarasa, M. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.08.006 · Cited by 2
Advancing beyond reverse transcriptase inhibitors: The new era of hepatitis B polymerase inhibitors
Ranga, A., Gupta, A., Yadav, L., Kumar, S., & Jain, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115455 · Cited by 2
Hou, L., Zhao, J., Cai, L., Jin, L., Liu, B., Li, S., Yang, J., Ji, T., Li, S., Liang, S., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29607 · Cited by 2
“…diverse functions, including protein ‐ primed initiation of reverse transcription, RNase H activity and RNA/DNA ‐ dependent DNA polymerase activity 18 Among the clinical drugs used for HBV treatment, nucleos(t)ide analogs (such as lamivudine and tenofovir) inhibit the activity of HBV polymerase,…”
Exploration des mécanismes de résistance du VHB à l'entécavir avec une approche phénotypique
Marlet, J. (2020) · theses.fr (ABES) · doi:10.70675/c30bd4fezbc58z4355zb58cz284cdd744fb6
Metadata
- Authors
- Vörös, J., Urbanek, A., Rautureau, G. J. P., O'Connor, M., Fisher, H. C., Ashcroft, A. E., & Ferguson, N.
- Affiliations
- University College Dublin (IE)
- University of Leeds (GB)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2014-03
- Volume
- 88
- Issue
- 5
- Pages
- 2584-2599
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3958071
- OpenAlex
- W2085965763
- Cited by
- 27
- References
- 89
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2020: 6 · 2019: 4 · 2018: 1 · 2016: 3 · 2015: 3 · 2014: 4
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- hepatitis B virus, viral polymerase, recombinant protein expression, protein purification, protein aggregation, protein structure, reverse transcriptase activity, metal ion binding, calmodulin, calmodulin antagonists, antiviral drug discovery, therapeutic target
- MeSH terms
- Algorithms, Circular Dichroism, Hepatitis B virus, Humans, Models, Molecular, Protein Binding, Recombinant Proteins, Ribonucleoproteins, Mass Spectrometry, Gene Products, pol, Protein Structure, Secondary, Protein Interaction Domains and Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.